The effect of tafamidis on the QTc interval in healthy subjects.

about

Mechanism of Action and Clinical Application of Tafamidis in Hereditary Transthyretin Amyloidosis Functional Amyloid Signaling via the Inflammasome, Necrosome, and Signalosome: New Therapeutic Targets in Heart Failure A Review of Tafamidis for the Treatment of Transthyretin-Related Amyloidosis.

P2860

Q26764754-F15DCCC6-4801-4C94-AA59-57F7F722E69A Q26776120-68F2E6B1-E9F9-4858-B1FD-C0B26D093396 Q36389712-C6F5F477-0EDE-4A25-9701-94668A55D0BE

P2860

The effect of tafamidis on the QTc interval in healthy subjects.

Item

http://www.wikidata.org/entity/Q35684808

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

The effect of tafamidis on the QTc interval in healthy subjects.

@ast

The effect of tafamidis on the QTc interval in healthy subjects.

@en

type

Item

label

The effect of tafamidis on the QTc interval in healthy subjects.

@ast

The effect of tafamidis on the QTc interval in healthy subjects.

@en

prefLabel

The effect of tafamidis on the QTc interval in healthy subjects.

@ast

The effect of tafamidis on the QTc interval in healthy subjects.

@en

P1476

The effect of tafamidis on the QTc interval in healthy subjects.

@en

P2093

Eric Watsky

http://www.w3.org/2001/XMLSchema#string

Karen J Klamerus

http://www.w3.org/2001/XMLSchema#string

Robert Moller

http://www.w3.org/2001/XMLSchema#string

Ronnie Wang

http://www.w3.org/2001/XMLSchema#string

Steve Riley

http://www.w3.org/2001/XMLSchema#string

P2860

The structure of human retinol-binding protein (RBP) with its carrier protein transthyretin reveals an interaction with the carboxy terminus of RBP

Structure of a complex of two plasma proteins: transthyretin and retinol-binding protein

Pathogenesis of and therapeutic strategies to ameliorate the transthyretin amyloidoses.

Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial

Prevention of transthyretin amyloid disease by changing protein misfolding energetics.

Transthyretin mutations in hyperthyroxinemia and amyloid diseases.

Guideline of transthyretin-related hereditary amyloidosis for clinicians.

Sequence-dependent denaturation energetics: A major determinant in amyloid disease diversity.

Transthyretin and familial amyloidotic polyneuropathy. Recent progress in understanding the molecular mechanism of neurodegeneration.

Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy.

P304

918-925

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/BCP.12561

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25546001

http://www.w3.org/2001/XMLSchema#string

P932

4456124

http://www.w3.org/2001/XMLSchema#string

The effect of tafamidis on the QTc interval in healthy subjects.

about

P2860

P2860

The effect of tafamidis on the QTc interval in healthy subjects.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932